Therapeutic
Solutions International Obtains Exclusive License for Patented
Clinical Stage Adult Stem Cell for Treatment of Military and Sports
Brain Injuries
OCEANSIDE, CA --
July 1, 2019 -- InvestorsHub NewsWire -- Therapeutics
Solutions International, Inc., (OTC Markets: TSOI)
announced recently signing of a license agreement providing
exclusive rights to a patented [1] adult stem cell for development
of therapeutics in the area of chronic traumatic encephalopathy
(CTE) and traumatic brain injury (TBI).
The
stem cell licensed, termed "JadiCell" is unique in that it
possesses features of mesenchymal stem cells, however, outperforms
these cells in terms of a) enhanced growth factor production; b)
augmented ability to secrete exosomes; and c) superior angiogenic
and neurogenic ability
[2].
Chronic
Traumatic Encephalopathy (CTE) is caused by repetitive
concussive/sub-concussive hits to the head sustained over a period
of years and is often found in football players. The condition is
characterized by memory loss, impulsive/erratic behavior, impaired
judgment, aggression, depression, and dementia. In many patients
with CTE, it is anatomically characterized by brain atrophy,
reduced mass of frontal and temporal cortices, and medial temporal
lobe. TSOI has previously filed several patents in the area
of CTE based on modulating the brain microenvironment to enhance
receptivity of regenerative cells such as stem cells.
"As a
practicing physician, I witness firsthand the devastation caused in
our Combat Veterans, as well as Professional Athletes, from CTE and
TBI" said Dr. James Veltmeyer, Chief Medical Officer of Therapeutic
Solutions International. "Given that these cells are subject
of a cleared FDA IND for another indication, we believe we are
uniquely positioned to accelerate development of
JadiCell's.
Suicide
is a major cause of death in military veterans, approximately 20
deaths per day [3]. It is widely known that TBI and CTE are
associated with increased propensity for suicide [4,5].
Furthermore, studies show that cytokines associated with brain
inflammation, such as IL-6 and TNF-alpha are found in higher levels
in patients with suicidal tendencies [6].
"Successful
treatment of neuroinflammation is the Holy Grail of therapeutic
neurology" said Dr. Santosh Kesari, MD, PhD, Director of Pacific
Neurosciences Institute and Scientific Advisory Board Member of
TSOI. "The fact that the JadiCell's
are anti-inflammatory, neuroregenerative, and effectively cross the
blood brain barrier, make these cells exciting candidates for
addressing the urgent need in patients with TBI and
CTE. I look forward to
working alongside Timothy Dixon and his team to get this extremely
promising therapeutic into the clinic."
"I am
honored that a stem cell luminary as powerful as Dr. Amit Patel,
the first physician to inject stem cells into the human heart, has
entrusted our Company with his potent and promising technology
as applied to brain
injuries" said Timothy Dixon, President and CEO of TSOI. "We look
forward to filing an IND for this technology before year
end."
About
Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation
for the treatment of several specific diseases. Immune modulation
refers to the ability to upregulate (make more active) or
downregulate (make less active) one's immune system. The Company's
corporate website is at
www.therapeuticsolutionsint.com
and our e-commerce is at
www.youcanordernow.com
and for additional info on NanoStilbene visit
www.mynanostilbene.com.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure, or prevent any disease.
[1] https://patents.google.com/patent/US9803176?oq=9803176
[2] https://www.ncbi.nlm.nih.gov/pubmed/23057960
[3]
https://en.wikipedia.org/wiki/United_States_military_veteran_suicide
[4]
https://www.psychcongress.com/news/traumatic-brain-injury-tied-increased-risk-suicide
[5]
https://sbindependent.org/nfl-athletes-with-cte-who-committed-suicide/
[6]
https://www.ncbi.nlm.nih.gov/pubmed/20951793
Safe
Harbor Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. The reader is cautioned not
to put undue reliance on these forward-looking statements, as these
statements are subject to numerous risk factors as set forth in our
SEC filings. To the extent that statements in this press release
are not strictly historical, including statements as to product
launch timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
Contact
Information: